Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
In an update issued on Tuesday, the FDA classed the recalls as Class II, which is when the "use of or exposure to a violative product may cause temporary or medically reversible adverse health ...